SOLTF fundamentals

Nxera Pharma Co., Ltd. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company engages in the research, development and sales of medicines; management of regenerative medical funds; investment in bio venture companies related to regenerative medicines; overseas development by licensing; promotions of commercialization; structural analysis of GPCR; initial lead compound creation; candidate search by proprietary StaR (Stabilised Receptor) technology; as well as structural base of new drugs using GPCR related basic technology drug discovery and screening and promotions of antibody drug research and development. The company was founded by Shinichi Tamura and Takaya Nakamura on June 22, 1990 and is headquartered in Tokyo, Japan.